Medical products companies are increasingly challenged to demonstrate the value of new products — in particular by payers who are demanding hard comparative economic and clinical value (ECV) data to justify premium pricing, price increases and sometimes just to maintain the status quo. On a global basis, government health authorities are increasingly requiring economic and clinical evidence as cost containment becomes a central issue. Individual physicians remain important, but the power of payers and organized provider groups to impact market access, product uptake and profitability is rapidly growing.

Read More

Thank you for your interest in our content. Registering allows you to access a wide range of informative articles, briefs, and whitepapers throughout the site.

Privacy is important. We do not share registrant information with anyone outside of Numerof & Associates. For details, please see our Privacy Policy. Subscribers to our mailings can unsubscribe instantly at any time.

×